The mechanism underlying the amelioration of SLE disease after NKG2D antibody treatment might involve blockade of the interaction between NKG2D+CD4+ T cells and Treg cells, thereby causing restoration of the Treg frequency as observed in treated mice. Here, KLRK1 is linked to systemic lupus erythematosus.